On the practical application of mixed effects models for repeated measures to clinical trial data

Pharmaceutical Statistics

Volumn 12, Issue 1, 2013, Pages 7-16

  Andersen, Scott W ^a   Millen, Brian A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

LOCF; missing data; MMRM

Indexed keywords

ANALYSIS OF COVARIANCE; ANALYTIC METHOD; ARTICLE; CLINICAL TRIAL (TOPIC); HUMAN; MIXED EFFECT MODELS FOR REPEATED MEASURE; SIMULATION; SYSTEMATIC ERROR;

BIAS (EPIDEMIOLOGY); CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; HUMANS; MODELS, STATISTICAL; PATIENT DROPOUTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84872487320     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.1548     Document Type: Article

References (12)

1. Panel on Handling Missing Data in Clinical Trials, National Research Council, Committee on National Statistics, Division of behavioral and Social Sciences and Education. The Prevention and Treatment of Missing Data in Clinical Trials. The National Academies Press: Washington DC, 2010.
2. Mallinckrodt C, Kaiser C, Watkin J, Detke M, Molenberghs G, Carroll R,. Type I error rates from likelihood-based repeated measures and analyses of incomplete longitudinal data. Pharmaceutical Statistics 2004; 3: 171-186.
3. Mallinckrodt CH, Clark WS, David SR,. Accounting for dropout bias using mixed-effects models. Journal of Biopharmaceutical Statistics 2001; 11 (1): 9-21.
4. Lane P,. Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharmaceutical Statistics 2008; 7: 93-106.
5. Mallinckrodt C, Kaiser C, Watkin J, Molenberghs G, Carroll R,. The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVA. Clinical Trials 2004; 1: 477-489.
6. Gueorguieva R,. Move over ANOVA: Progress in analyzing repeated-measures data and its reflection in papers published in the archives of general psychiatry. Archives of General Psychiatry 2004; 61 (3): 310-317.
7. Siddiqui O, Hung J, O'Neill R,. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. Journal of Biopharmaceutical Statistics 2009; 19: 227-246.
8. Fisher LD, Dixon DO, Herson J, Frankowski RK, Hearron MS, Peace KE,. Intention-to-Treat in clinical trials. Statistical Issues in Drug Research and Development, Peace KE, (ed.). Marcel Dekker: New York.
9. Molenberghs G, Thijs H, Jansen I, Beunckens C, Kenward MG, Mallinckrodt C, Carroll RJ,. Analyzing incomplete longitudinal clinical trial data. Biostatistics 2004; 5: 445-464.
10. Shao J, Zhong B,. Last observation carry-forward and last observation analysis. Statistics in Medicine 2003; 22: 2429-2441.
11. Mallinckrodt C, Lane P, Schnell D, Peng Y, Mancuso J,. Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials. Drug Information Journal 2008; 42: 303-319.
12. European Medicines Agency (EMEA) Guideline on Missing Data in Confirmatory Clinical Trials released April 2009 (CPMP/EWP/1776/99 Rev. 1 Corr).